Ketamine and OCD: The Latest Research
For many people, obsessive-compulsive disorder or OCD involves relentless intrusive thoughts, fears, and repetitive behaviors that can consume hours each day and significantly impacts quality of life. While traditional treatments such as selective serotonin reuptake inhibitors (SSRIs) and Exposure and Response Prevention (ERP) therapy remain the standard of care, a growing body of research suggests that ketamine may offer a promising new option for individuals with treatment-resistant OCD.
A recent 2026 review published in Pharmaceuticals examined the emerging evidence surrounding ketamine and esketamine for OCD treatment. Researchers found that ketamine appears capable of producing rapid reductions in obsessive thoughts and symptoms, often within hours or days rather than the weeks or months typically required with conventional treatments.
One reason ketamine has generated so much interest is that OCD may involve more than serotonin imbalance alone. Increasing evidence suggests that glutamate, the brain's primary excitatory neurotransmitter, also plays a critical role in the development and persistence of obsessive thinking and compulsive behaviors. Ketamine works differently than traditional psychiatric medications by modulating glutamate signaling and promoting neuroplasticity—the brain's ability to form new connections and adapt.
Many patients with OCD describe feeling trapped in repetitive mental loops. The review found that ketamine may temporarily reduce the "stickiness" of obsessive thoughts, allowing individuals to experience greater mental flexibility and decreased urgency around compulsive behaviors. Interestingly, obsessive thoughts often appear to improve before compulsive actions, suggesting ketamine may help disrupt the underlying thought patterns that drive the disorder.
Researchers are also increasingly interested in ketamine's effects on memory and learning. Our brains continuously strengthen and reinforce patterns of thinking through a process called memory consolidation. In OCD, fear-based associations and repetitive thought patterns can become deeply ingrained over time.
Ketamine appears to create a temporary period of enhanced neuroplasticity during which memories and established emotional responses become more malleable. This process, known as memory reconsolidation, may allow individuals to revisit previously distressing thoughts or experiences while forming new, healthier associations. Rather than erasing memories, ketamine may help the brain update and reorganize them in ways that reduce emotional distress and behavioral rigidity.
This may be one reason ketamine-assisted psychotherapy (KAP) and other forms of therapy can be particularly powerful when paired with ketamine treatment. During this window of increased flexibility, patients may find it easier to challenge longstanding beliefs, engage in therapeutic exercises, and develop new coping strategies.
The review also found that repeated ketamine treatments may provide more durable benefits than a single session, although researchers emphasize that larger studies are still needed. While the evidence remains preliminary, the findings are encouraging for individuals who have not responded adequately to traditional OCD treatments.
At Áureo Clinic, we believe ketamine is most effective when used as part of a comprehensive, individualized treatment plan. By combining ketamine's ability to promote neuroplasticity with thoughtful preparation, psychotherapy, and integration support, patients may be better able to translate temporary symptom relief into meaningful long-term change.
For individuals seeking Anxiety Treatment Oregon services who struggle with OCD, ketamine represents an exciting area of ongoing research and clinical innovation. While it is not yet considered a first-line treatment for OCD, current evidence suggests it may offer hope for those who continue to suffer despite conventional approaches.
References:
Robbins MS, Stern ER. Ketamine and esketamine in obsessive-compulsive disorder. Pharmaceuticals (Basel). 2026;19(4):628.
Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013;38(12):2475-2483.
Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci. 2015;1344(1):66-77.
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
Dr. Lindsay Wilkinson, ND, is a compassionate naturopathic doctor dedicated to empowering her patients to achieve optimal health and well-being.
With a focus on integrative medicine, she combines evidence-based treatments with holistic approaches to address a wide range of health concerns. Dr. Wilkinson's passion lies in guiding her patients toward balanced wellness through personalized care and support.